Phase IB Study of Phenoxodiol Given by Constant Intravenous Infusion in Patients With Solid Neoplasms (With the Exception of Breast Cancer) Whose Tumors Are Refractory to Standard Therapy

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed solid tumor

- Refractory to standard therapy OR

- No standard therapy exists

- No breast cancer

- No active CNS metastases

- Known CNS metastases must be previously treated with radiotherapy or surgery and
stable for at least 4 weeks prior to study

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Karnofsky 60-100%

Life expectancy:

- At least 3 months

Hematopoietic:

- Platelet count greater than 100,000/mm^3

- WBC greater than 3,000/mm^3

- Neutrophil count greater than 1,500/mm^3

- Hemoglobin greater than 10 g/dL (9 g/dL for women)

Hepatic:

- Bilirubin less than 1.2 mg/dL

- Transaminases no greater than 3 times upper limit of normal

Renal:

- Creatinine no greater than 1.4 mg/dL

Other:

- No active infection

- No contraindication to the insertion of a vascular access device

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No concurrent systemic anticancer immunotherapy

Chemotherapy:

- No concurrent systemic anticancer chemotherapy

Endocrine therapy:

- No concurrent systemic anticancer hormonal therapy except luteinizing
hormone-releasing hormone agonists or antagonists

Radiotherapy:

- See Disease Characteristics

- Concurrent localized radiotherapy for control of local disease complications allowed

Surgery:

- See Disease Characteristics

Other:

- Recovered from prior antineoplastic therapy

- At least 4 weeks since prior investigational agents

- No other concurrent investigational drugs